PRODUCT DETAILS
- RLD: PLETAL®
- Strength: Available in 50 mg and 100 mg tablets
- Therapeutic Class: Phosphodiesterase III Inhibitor
PRODUCT DETAILS
| Strength | NDC Number | Saleable Unit | Wholesaler Numbers |
|---|---|---|---|
| 50 mg | 70436-156-06 | Bottle of 60 | Cardinal Health: 5709308 |
| McKesson: 2305993 | |||
| Amerisource: 10255199 | |||
| 100 mg | 70436-157-06 | Bottle of 60 | Cardinal Health: 5709316 |
| McKesson: 2306009 | |||
| Amerisource: 10255286 |
50 mg: White, round tablets, one side debossed “YH205”; the other side plain.
100 mg: White, round tablets, one side debossed “YH210”; the other side plain
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant, child-resistant container as defined in the USP. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
WARNING: CONTRAINDICATED IN HEART FAILURE PATIENTS
Cilostazol tablets are contraindicated in heart failure of any severity. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure.
Cilostazol Tablets are contraindicated in patients with:
Cilostazol may induce tachycardia, palpitation, tachyarrhythmia, or hypotension. Patients with a history of ischemic heart disease may be at risk for exacerbations of angina pectoris or myocardial infarction.
Left ventricular outflow tract obstruction has been reported in patients with sigmoid shaped interventricular septum. Monitor patients for the development of a new systolic murmur or cardiac symptoms after starting cilostazol.
Cases of thrombocytopenia or leukopenia progressing to agranulocytosis when cilostazol was not immediately discontinued have been reported. Agranulocytosis is reversible on discontinuation of cilostazol.
Cilostazol inhibits platelet aggregation in a reversible manner. Cilostazol has not been studied in patients with hemostatic disorders or active pathologic bleeding. Avoid use of cilostazol in these patients.
The most common adverse reactions (greater than or equal to 2% and at least twice that for placebo) in patients on 100 mg twice daily are headache, diarrhea, abnormal stools, and palpitation.
Please see the package insert for Cilostazol Tablets for full prescribing information.
We have been made aware of recent scams that offer false employment opportunities or request financial commitments purportedly on behalf of Slate Run Pharmaceuticals. Unsuspecting job seekers have reported receiving unsolicited contacts such as e-mails and phone calls which may request personal information or offers of employment. Please note that these communications are fraudulent and are not affiliated with Slate Run Pharmaceuticals. Slate Run Pharmaceuticals never requires a financial deposit for employment consideration nor do we offer unsolicited employment packages.
You can reach out to Slate Run Pharmaceuticals at http://www.slaterunpharma.com/get-in-touch/. If you receive a suspicious proposal, please contact your local law enforcement agency for guidance.